Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)
NCT03164915Phase 3Completed
- Sponsor
- SK Plasma
- Start
- Oct 2016
- Primary completion
- Apr 2018
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of polyvalent human immunoglobulin in immune thrombocytopenia (ITP), sponsored by SK Plasma. Primary endpoint: Responder rate (CR or R) at 28 days. Started Oct 2016; status: completed.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT03164915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03164915.